Small-cap health care company Lexaria Bioscience has moved 16.6% this afternoon, reaching $0.86 per share. In contrast, the average analyst target price for the stock is $14.0.
Lexaria Bioscience Corp. operates as a biotechnology company. The company is based in Canada.
What to Consider if You Are Thinking of Buying Lexaria Bioscience:
-
Lexaria Bioscience has moved -65.6% over the last year.
-
LEXX has a forward P/E ratio of -1.0 based on its EPS guidance of -0.84.
-
Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of 7.7%.
-
Its Price to Book (P/B) ratio is 1.03
Lexaria Bioscience Has Negative Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cashflow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-08-31 | -4,879 | -131 | -5,011 | -23.14 |
| 2021-08-31 | -3,990 | -79 | -4,069 | -50.88 |
| 2020-08-31 | -2,663 | -34 | -2,697 | 28.55 |
| 2019-08-31 | -3,006 | -769 | -3,775 | n/a |
Averaging $-3.89 Million over the last 4 years, Lexaria Bioscience has consistently negative free cash flows. Their compounded average growth rate over this period is -7.3%, and their coefficient of variability is 24.5%.
